In our last review of CRISPR Therapeutics (CRSP) on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses."
More from Investing
As the action cools, there is going to be more concern about how easy it will be for this market to continue to rally at this pace.
Just when is the Federal Reserve going to reduce the cash slosh, anyway?
Let's look at breadth on the S&P 500, the put/call ratio, the bonds, the overbought market, and more.